Peptide Merchant Account Terminated? What Happens Next

If your peptide merchant account was just terminated, the useful move this week is not finding somewhere new to apply. It is getting two answers in writing from the processor that closed you, the stated reason for the closure and whether you were reported to the card networks’ terminated merchant databases. Those two facts decide which payment rails stay open, how long the problem lasts, and what the next underwriter sees before you get a chance to explain anything. They are also the hardest facts to collect once your dashboard is gone and your contact stops replying. The first week does more work here than the next two months.

Key takeaways

• Acquiring banks must screen every applicant against the terminated merchant databases, and on MATCH must add a qualifying merchant within one business day of termination (Stripe, terminated merchant files).
• Listings stay active for five years, and only the bank that filed one can correct or remove it (Stripe, terminated merchant files).
• The reason code matters more than the listing itself. A chargeback code and a rule-violation code send you down different routes.
• A listing restricts the Visa and Mastercard rails specifically. Bank-account debit settles over ACH rails those networks do not gate.
• The 2026 federal peptide news does not strengthen your application. It concerns compounding pharmacies, not research-use-only ecommerce.

Why a peptide closure arrives without a real explanation

Most processors never wrote a peptide rule, so in most cases there is no rule for the closure notice to cite. What you get instead is a line about a violation of the terms, or a general reference to prohibited activity, and no detail about which part of your business produced it.

That vagueness is not an accident and it is not personal. Peptide accounts are usually ended under the broad discretion every processor agreement already reserves, which is a separate mechanism from a published category ban. We covered how that works in why processors decline peptide sellers, and you can read the actual published policies for eight major platforms in our prohibited businesses lookup.

Here is why it matters right now. A discretionary closure still gets a formal characterization if your acquirer reports it, and that characterization is a short code in a database rather than the sentence in your email. The code is what follows you. The email does not.

Were you reported, and under which code?

Ask the question directly and in writing. Two databases are involved, Mastercard’s MATCH and Visa’s VMSS, and they are collectively called terminated merchant files or TMF. Acquirers must screen every applicant against them before approval, and must report any merchant they terminate for fraud, severe policy violations, or excessive chargebacks (Stripe, terminated merchant files). On MATCH, an acquirer that terminates a qualifying merchant has one business day to add them.

You cannot search either database yourself. Both are closed systems for acquiring banks. So you have two ways to learn where you stand. Ask the processor that closed you, or apply somewhere new and let the required screening surface it.

The code attached to a listing is the part worth chasing. MATCH sorts listings into eleven rule-based reason codes plus two numeric ones, and VMSS uses thirteen rule-based codes plus two numeric ones (Stripe, terminated merchant files). The numeric codes are mechanical. On MATCH, excessive chargebacks means monthly Mastercard chargebacks above 1% of monthly Mastercard sales that also total 5,000 USD or more in the same month. Excessive fraud means a fraud-to-sales dollar ratio of 8% or more, with at least 10 fraudulent transactions totaling 5,000 USD or more in one calendar month. On VMSS, excessive disputes means 1,000 disputes and a 1.8% dispute-to-sales ratio in a single month.

Peptide sellers are frequently closed well below those numbers, which tells you something useful. If your dispute volume never came close to those lines, your listing was probably filed under one of the rule-based codes instead. Those are judgment calls made by your former acquirer. A code describing a rule violation is your old bank’s characterization of what happened. It is not a legal finding about your business, and a new underwriter who reads the category regularly knows the difference.

Two more rules shape what you can do about it. Records stay active for five years, and only the bank that filed the entry can modify or delete it, generally where the entry was made in error (Stripe, terminated merchant files). If you do not know which bank filed it, Mastercard publishes a mailbox at [email protected] for merchants asking about their own listing.

The general sequence for any closure, including your held funds and your reserve balance, is covered in what to do after a merchant account termination. The rest of this page is the part that is specific to peptides.

What to do in the first week that peptide sellers get wrong

Three items are easy to miss, and all three get harder every day you wait.

1. Archive your storefront before you change a word of it. Save full-page captures of your product pages, your disclaimers, your checkout, and your policy pages exactly as they were on the day you were closed. You are about to rewrite them, and once you do, you can no longer show the next underwriter what the last processor actually saw. Merchants who clean up first and ask questions later end up unable to describe their own case.
2. Answer the disputes that are still open. Chargebacks filed before your closure do not disappear with the account, and a dispute you never responded to still counts against you on the file a new underwriter reads. Accertify’s 2023 to 2024 client data puts the median win rate at about 57% on non-fraud disputes and about 37% on fraud-coded ones, so the winnable ones repay the hours. The process is in how to fight a chargeback.
3. Put your product documentation in one folder now. Certificates of analysis for the compounds you sell, your supplier records, your research-use labeling, and your age-verification setup at checkout. These are the documents an underwriter who actually reviews the category will ask for, and hunting for them mid-application is how a fixable application stalls.

One thing to skip. Do not spend the week appealing. Reinstatement is rare, because the decision generally sits with the bank behind the platform rather than the support agent answering you. The weeks you spend arguing are the weeks you needed for reboarding.

Does the 2026 FDA peptide news help your application?

No, and citing it will not improve how a risk team reads your file. It is worth knowing what actually happened, because a lot of coverage overstated it.

On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2 of the 503A bulk drug substances framework, because the people who nominated them withdrew the nominations. Removal is not permission. In Orrick’s wording, removal from Category 2 does not by itself place these substances on the 503A bulks list or into Category 1. They sit in a gray area rather than an approved one.

Then in July 2026 the Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A list and voted against a seventh. That committee advises. Its votes are recommendations and are not binding on the FDA, and formal approval at the department level is still required before pharmacies can compound those substances (NCPA). Rulemaking after a recommendation like this can take more than a year.

Both stories concern licensed pharmacies compounding for patients with prescriptions. Neither one touches research-use-only ecommerce, and neither one changes how a processor reads your store. It is also worth saying plainly that research-use-only labeling is not a legal safe harbor. Under federal rules on intended use (21 CFR 201.128), what a product is intended for is judged from the whole picture. That picture includes your advertising and how you sell. A disclaimer does not settle a question the rest of the page has already answered. Underwriting reads it the same way, as one signal among several.

What a listing blocks, and what it does not

A terminated merchant file entry restricts the Visa and Mastercard rails. It does not switch off every way to collect money, and this is the point most merchants miss in the first two weeks.

Bank-account debit, often called e-debit or ACH debit, pulls funds directly from your customer’s bank account rather than running a card transaction. Those rails are not gated by the card networks, so an e-debit account can be boarded regardless of listing status. On that rail specifically, approval is same-day and funding is next-day. Those figures describe e-debit only. Card processing runs through real underwriting and is reviewed against your reason code, case by case, on its own timeline.

That distinction is what keeps a business trading during the period when most owners assume they have no options at all. It is not credit card acceptance and nobody should sell it to you as such. Our MATCH and TMF processing options page sets out how the two paths run alongside each other.

How to get placed again

Reboard with someone who underwrites peptides on purpose, and lead with the closure rather than waiting to be asked. Every processor is required to screen you anyway, so a hidden termination surfaces on its own and turns a routine review into a trust problem.

Have this ready before you apply.

• The stated closure reason in writing, and your reason code if you have it.
• Three to six months of processing statements from the closed account.
• Your current chargeback ratio, and what you changed to bring it down.
• A plain description of your catalog, including anything you have stopped selling.
• Your certificates of analysis, labeling, and age-verification details.

Two specifics for this category. First, if you sell SARMs alongside research peptides, expect the SARMs to set the terms for the whole application. The FDA treats SARMs as unapproved new drugs, a firmer federal position than research peptides carry, and risk teams know it. Decide in advance whether that line stays in the catalog. Second, the product pages you rewrote this week are part of the application. Dosing charts, injection instructions, and before-and-after photos are read as evidence about what the product is for, whatever the footer says.

Be skeptical of two offers you will see while searching. Anyone advertising guaranteed approval is describing a decision they do not control. Anyone selling delisting for a fee is selling something the network rules do not support, because only the filing bank can correct an entry. A real answer to your situation is specific about what your category can support and what your history can.

The short version

A peptide termination is a setback with a known shape. Get the closure reason in writing, ask whether you were reported and under which code, archive your storefront before you change it, and answer your open disputes. Then apply somewhere that reviews the labeling, the documentation, and the dispute profile up front instead of discovering them six months in. That up-front review is what peptide merchant accounts are built around. If a listing is already in play, the MATCH and TMF processing options page covers what still works while the card side is reviewed. Start your application when your file is together, and we will discuss pricing against your current processing once we have talked.